Clinical Trials Logo

Filter by:
NCT ID: NCT03687060 Active, not recruiting - Clinical trials for Cardiovascular Diseases

INcreasing Statin Prescribing in HIV Behavioral Economics REsearch

INSPIRE
Start date: March 4, 2019
Phase: N/A
Study type: Interventional

Cardiovascular disease is a major cause of morbidity and mortality among people living with HIV. Recent studies have demonstrated that patients with HIV experience a 50-100% increased risk of myocardial infarction and stroke compared to HIV-uninfected persons. They also face higher risks of stroke, sudden death, and heart failure. However, evidence-based statin therapy-which is safe in this population and highly effective at reducing cardiovascular risk-is under-prescribed. The investigators propose a multi-level intervention to increase evidence-based statin prescribing by addressing barriers at these levels. The implementation intervention includes two strategies: (1) tailored education at the leadership, provider, and patient levels, and (2) behavioral economics-informed feedback for providers.

NCT ID: NCT03686683 Active, not recruiting - Clinical trials for Adenocarcinoma of the Prostate

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

ProVent
Start date: October 18, 2018
Phase: Phase 3
Study type: Interventional

The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to subjects followed on active surveillance as standard of care.

NCT ID: NCT03686488 Active, not recruiting - Gastric Cancer Clinical Trials

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Start date: December 20, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if the combination of TAS 102 and Ramucirumab is safe and effective in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.

NCT ID: NCT03686007 Active, not recruiting - Caregiver Clinical Trials

Multimedia Self-Management Intervention for Lung Cancer Surgery Family Caregivers and Patients

Start date: November 6, 2018
Phase: N/A
Study type: Interventional

This randomized phase III trial studies how well a multimedia self-management intervention works in preparing family caregivers and patients with stage I-III lung cancer for lung cancer surgery. The multimedia self-management intervention, Preparing for your Lung Cancer Surgery, is a nurse-led, caregiver-based, multimedia intervention that may improve patient recovery after surgery, lower caregiving burden, and improve distress and quality of life.

NCT ID: NCT03685461 Active, not recruiting - Hearing Loss Clinical Trials

AB-Intra- and Post-Operative Measures of Auditory Function

AB-ECOG
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to see how the inner ear responds to sound delivered to the ear canal during and after your cochlear implant surgery. This information may be helpful in telling us how well a cochlear implant performs after surgery.

NCT ID: NCT03685331 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Start date: October 15, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast cancer and BRCA1 or BRCA2 mutations.

NCT ID: NCT03684889 Active, not recruiting - Lymphoma Clinical Trials

CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma

Start date: November 28, 2018
Phase: Phase 1
Study type: Interventional

Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a fully human chimeric antigen receptor (CAR). The CAR used in this study can recognize CD19, a protein expressed on the surface of leukemia and lymphoma cells. The fully human CAR used in this study may help protect against rejection of the CAR T cells, which in turn could lead to lasting protection against return of the leukemia or lymphoma. The phase 1 part of this study will determine the safety of these CAR T cells, and the phase 2 part of the study will determine how effective this CAR T cell therapy is. Both patients who have never had prior CAR T cell therapy and those who have had prior CAR T cell therapy may be eligible to participate in this study.

NCT ID: NCT03684590 Active, not recruiting - Acute Pain Clinical Trials

ANI Versus Standard Care in Surgical Patients Receiving Balanced Sevoflurane-Fentanyl Anesthesia

Start date: July 30, 2019
Phase: N/A
Study type: Interventional

This study aims to be a randomized, controlled study of ANI-guided opioid administration versus standard clinical practice in surgical patients undergoing general anesthesia with balanced sevoflurane-fentanyl. Patients will be randomly assigned to 2 groups- ANI vs. standard care. The intraoperative and postoperative management of all patients will be standardized by protocol. The PACU nurses and postop assessor will be blinded as to which group the patient is in.

NCT ID: NCT03684447 Active, not recruiting - Clinical trials for Treatment Resistant Depression

Neural and Antidepressant Effects of Propofol

Start date: April 21, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This study will compare the antidepressant effects of propofol at two different doses while measuring potential treatment-related biomarkers.

NCT ID: NCT03683225 Active, not recruiting - Clinical trials for Idiopathic Parkinson Disease

A Study to Evaluate in Patients With Parkinsonian Type Disorders

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

A Phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with parkinsonian type disorders